BioPharmSignal logoBioPharmSignal

Biotech News

Enlivex Announces Termination of Previously-Announced Financing Payable in RAIN Tokens

Enlivex Therapeutics (ENLV)Enlivex TherapeuticsFinancing

Nes-Ziona, Israel, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced the termination of a securities purchase agreement entered into with the Rain Foundation, pursuant to which the Company had agreed, subject to shareholder approval,...

Related news

ENLVEnlivex Therapeutics2026-10-27 13:00 EST

Enlivex Announces Receipt of Delisting Notice from Nasdaq; Intends to Appeal

ENLVEnlivex Therapeutics2026-10-22 22:16 EST

Enlivex Announces 1-for-16 Reverse Share Split to be Effective October 27, 2026

PDSBPDS Biotechnology Corporation2026-09-14 14:30 EST

PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors

TPSTTempest Therapeutics2026-09-11 12:00 EST

Tempest Therapeutics Announces Up to $7.5 Million Private Placement

PDSBPDS Biotechnology Corporation2026-09-08 12:30 EST

PDS Biotech Announces up to $22.55 Million Financing Led by Dr. Patrick Soon-Shiong, Founder of NantWorks

RHHBYRoche Holdings AG2026-10-27 06:00 EST

Roche receives CE Mark for cobas® smart e immunoanalyser, completing a portfolio that brings central-lab precision to healthcare settings ranging from small clinics to large hospital laboratories

LYELLyell Immunopharma2026-11-04 14:02 EST

Lyell Immunopharma Announces $80 Million Private Placement to Advance Ronde-Cel Toward Planned BLA Submission

BMYBMYBristol-Myers Squibb Company2026-10-26 07:30 EST

Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study

RHHBYRoche Holdings AG2026-10-25 15:30 EST

Roche’s divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer

View all latest news

Enlivex Therapeutics

Enlivex Therapeutics is an immunotherapy company focused on macrophage reprogramming and inflammation-related disease. Its story is centered on harnessing innate immunity to address hard-to-treat conditions.

Recent company news

ENLVEnlivex Therapeutics2026-11-02 14:00 EST

Enlivex Announces Favorable 12-Month Topline Data from Phase I/IIa Allocetra Trial, Demonstrating Durable Treatment Response

ENLVEnlivex Therapeutics2026-10-28 13:00 EST

Enlivex Announces Randomization of 135 Patients in Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis

ENLVEnlivex Therapeutics2026-10-28 13:00 EST

Enlivex Announces Randomization of 135 Patients in Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis

ENLVEnlivex Therapeutics2026-10-27 13:00 EST

Enlivex Announces Receipt of Delisting Notice from Nasdaq; Intends to Appeal

ENLVEnlivex Therapeutics2026-10-27 13:00 EST

Enlivex Announces Receipt of Delisting Notice from Nasdaq; Intends to Appeal

Stock data

Close
1.27 USD
Market cap
204.87M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States